Heterocyclic silicon compounds and their use in the treatment of diseases or conditions associated with gnrh (gonadotropin-releasing hormone)

A pharmaceutical composition comprising a compound of formula (I)

• wherein
• one of X and Y is silicon, and the other is carbon or silicon;
• Z is oxygen, sulphur or —N(R)—, wherein R is hydrogen or alkyl;
• R1 is hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy or cycloalkyl;
• and
• R2 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -alkyl-cylcoalkyl, -alkyl-heterocycloalkyl, -alkyl-aryl or -alkyl-heteroaryl;
• or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

A method for the treatment or prevention of a disease or condition associated with GnRH wherein said method comprises administering a compound of formula (I)

• wherein
• one of X and Y is silicon, and the other is carbon or silicon;
• Z is oxygen, sulphur or —N(R)—, wherein R is hydrogen or alkyl;
• R1 is hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy or cycloalkyl;
• and
• R2 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -alkyl-cylcoalkyl, -alkyl-heterocycloalkyl, -alkyl-aryl or -alkyl-heteroaryl;
• or a pharmaceutically acceptable salt thereof;
• to a patient in need of such treatment.